but also some patients from Hong Kong, totaling 1600 patients with different etiologies and different levels of chronic liver disease. In that large study, we were able to show that in both the cohorts of patients from ...
but also some patients from Hong Kong, totaling 1600 patients with different etiologies and different levels of chronic liver disease. In that large study, we were able to show that in both the cohorts of patients from East and West,
2.Kanwal, F. et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology 155, 1828–1837.e2 (2018). 3.Chitturi, S. et al. The Asia–Pacific working party on non-alcoholic fatty liver disease guidelines 2017 — part 2: management and special g...
Wattacheril J. Nonalcoholic steatohepatitis (NASH): Diagnosis, treatment, and implications.Clin Liver Dis. 2018;22(1):1-10. Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease.J Clin Endo...
2.Kanwal, F. et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liverdisease. Gastroenterology 155, 1828–1837.e2 (2018). 3.Chitturi, S. et al. The Asia–Pacific working party on non-alcoholic fatty liver diseaseguidelines 2017 — part 2: management and special group...
Wattacheril J. Nonalcoholic steatohepatitis (NASH): Diagnosis, treatment, and implications. Clin Liver Dis. 2018;22(1):1-10. Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab. 2008;93(11_suppl_1). ...
1. Cotter, T. G. & Rinella, M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology 158, 1851–1864 (2020).2. Kiarash Riazi, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2022. ...
As with other liver diseases that cause cirrhosis, NAFLD increases the risk of liver cancer, a disease with poor outcomes and limited therapeutic options. The incidences of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma are also rising, and HCC is now the leading cause of ...
1. Targeted therapeutics and novel signaling pathways in non alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) 2. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease 3. Targeting fibrosis: mech...
Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress（来源：Arrowhead）[2] Abul-Husn, NS et al. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease. The New England journal of medicine (2018)